Chapter 38: Parallel Excellence
Day 162, the firm landed two major cases on the same day.
Harvey's announcement came first, loud enough for the entire bullpen to hear.
"Corporate espionage lawsuit. Former CTO of a Fortune 500 company allegedly stole trade secrets, started competing firm. Two hundred million in damages. Public trial. Mike's lead associate."
Applause from the associates. Mike looked excited and terrified.
Two hours later, Louis appeared at my desk.
"Pharmaceutical merger. Three companies consolidating—Cordova, BioDyne, and a European manufacturer. FDA approval required, EU competition law compliance, international regulatory coordination. Eight weeks to close or the deal collapses. You're running point."
No applause. No audience. Just work.
[WIN RATE CALCULATOR: INITIAL ASSESSMENT]
[SUCCESSFUL MERGER PROBABILITY: 61% (±14%)]
[COMPLEXITY: EXTREME - MULTI-JURISDICTION REGULATORY APPROVAL]
[TIMELINE: AGGRESSIVE - 8 WEEKS]
[VARIABLES: FDA PRE-MERGER REVIEW, EU COMPETITION LAW, IP TRANSFER COMPLICATIONS, EMPLOYEE STOCK OPTIONS ACROSS 400+ EMPLOYEES]
"When do we start?"
"Now."
Days 163 through 168 blurred into regulatory filings, conference calls across time zones, and System-enhanced document analysis.
I coordinated with three separate legal teams—Cordova's internal counsel, BioDyne's outside firm, and the European manufacturer's German attorneys who spoke perfect English but thought in a completely different legal framework.
FDA pre-merger approval required demonstrating the consolidation wouldn't reduce competition in critical drug markets. I built competitive analysis showing eight other manufacturers in each therapeutic area, sufficient competition remaining post-merger.
EU competition law demanded proof the merger wouldn't create market dominance. Different standard, different evidence, same goal—convince regulators this was pro-competitive consolidation, not anti-competitive monopolization.
[WIN RATE CALCULATOR: CONTINUOUS UPDATES]
[DAY 163: 61% SUCCESS PROBABILITY]
[DAY 165: 67% (FDA INITIAL APPROVAL)]
[DAY 167: 71% (EU PRELIMINARY CLEARANCE)]
[PROJECTING: 73% FINAL SUCCESS IF CURRENT TRAJECTORY MAINTAINED]
IP transfer was the nightmare scenario—patents held across three jurisdictions, licensing agreements that contradicted each other, technology sharing arrangements that created circular dependencies.
I spent eighteen hours on Day 166 untangling the patent portfolio, creating a unified IP structure that satisfied all three companies' concerns while maintaining regulatory compliance.
Employee stock options for 400+ employees across five countries required converting three different equity structures into one, preserving value while deferring tax consequences.
[ARGUMENT CRUSHER: REGULATORY OBJECTION PREPARATION]
[POTENTIAL FDA CONCERN: MARKET CONCENTRATION IN ONCOLOGY DRUGS]
[COUNTER: EIGHT REMAINING COMPETITORS, INCREASED R&D INVESTMENT]
[POTENTIAL EU CONCERN: TRANSFER PRICING MANIPULATION]
[COUNTER: THIRD-PARTY COMPARABLE PRICING, ARM'S LENGTH TRANSACTIONS]
Meanwhile, Harvey's espionage trial proceeded with media fanfare.
News coverage. Courthouse steps interviews. Dramatic witness testimony.
Mike was learning to perform. I was learning to execute.
Different skills. Both valuable.
Day 170, both cases resolved.
Harvey's trial settled at $187 million—client wanted $200 million, but settlement avoided appeal risk and guaranteed payment within sixty days.
Firm-wide celebration. Newsletter feature with photos. Harvey's victory speech about "tireless advocacy and courtroom excellence."
My merger closed at 4:47 PM.
All regulatory approvals secured. Three companies now unified. Zero complications. Zero media coverage.
Financial impact: Harvey's case generated $4.5 million in fees.
Louis's merger generated $6.2 million in fees plus ongoing relationship with the consolidated pharmaceutical company worth another $300,000 annually.
At the evening reception celebrating Harvey's victory, Louis pulled me aside.
"You and I need to talk about compensation."
"What?"
"You just ran a merger that generated more revenue than Harvey's trial. As an associate. That deserves recognition."
"I was doing my job."
"You were doing partner-level work. There's a difference."
Louis raised his voice slightly, addressing the associates nearby.
"Scott Roden deserves recognition for exceptional execution on highly complex technical work. The pharmaceutical merger closed flawlessly due to his efforts."
Polite applause. Nothing like Harvey's reception, but genuine.
Mike approached afterward.
"Heard your merger was technically impressive."
"Heard your trial was dramatic."
"Different kinds of law."
"Different kinds of lawyers. Both needed."
Mike nodded, understanding the implicit recognition that we weren't competing directly because we were playing different games entirely.
Donna found me near the exit.
"You and Louis make a good team."
"We complement each other. He handles relationships and negotiations. I handle structure and execution."
"That's partnership dynamics. You've essentially built a junior partnership with Louis."
The observation stopped me.
She's right. I'm not just Louis's associate anymore. I'm his strategic partner.
Ten months in, and I've built something that looks like a practice.
We left together, and Harvey watched from across the room—expression calculating, measuring, evaluating.
He sees it too. I'm not just an associate anymore.
That's either very good or very dangerous.
Probably both.
MORE POWER STONES And REVIEWS== MORE CHAPTERS
To supporting Me in Pateron .
with exclusive access to more chapters (based on tiers more chapters for each tiers) on my Patreon, you get more chapters if you ask for more (in few days), plus new fanfic every week! Your support starting at just $6/month helps me keep crafting the stories you love across epic universes like [ In The Witcher With Avatar Powers,In The Vikings With Deja Vu System,Stranger Things Demogorgon Tamer ...].
By joining, you're not just getting more chapters—you're helping me bring new worlds, twists, and adventures to life. Every pledge makes a huge difference!
👉 Join now at patreon.com/TheFinex5 and start reading today!